Tonmya's FDA approval on Aug. 15, 2025, was based on results from two Phase 3 studies involving nearly 1,000 patients. The most common side effects included mild mouth numbness or discomfort, altered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback